Analysts at Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) in a research note issued on Thursday, Marketbeat reports. The firm set an "overweight" rating and a $250.00 price target on the biotechnology company's stock. Morgan Stanley's target price suggests a potential upside of 43.62% from the company's current price.
Other analysts also recently issued reports about the company. Bank of America increased their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a report on Monday, June 9th. Wedbush increased their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Evercore ISI increased their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Oppenheimer reiterated an "outperform" rating and set a $224.00 price target (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Finally, JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $220.67.
Check Out Our Latest Report on ASND
Ascendis Pharma A/S Price Performance
NASDAQ ASND traded up $0.97 on Thursday, reaching $174.07. The company had a trading volume of 157,816 shares, compared to its average volume of 501,661. The firm has a market cap of $10.64 billion, a price-to-earnings ratio of -27.72 and a beta of 0.38. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The business has a 50 day moving average of $167.68 and a two-hundred day moving average of $152.36.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ascendis Pharma A/S
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. boosted its position in shares of Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company's stock worth $1,602,474,000 after purchasing an additional 168,752 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after purchasing an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after purchasing an additional 39,309 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after purchasing an additional 193,688 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its position in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock worth $475,970,000 after purchasing an additional 328,278 shares in the last quarter.
Ascendis Pharma A/S Company Profile
(
Get Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Read More

Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.